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Abstract
Background: PH domain Leucine-rich-repeats protein phosphatase (PHLPP) is a novel family of Ser/Thr protein
dephosphatases that play a critical role in maintaining the balance in cell signaling. PHLPP negatively regulates
PI3K/Akt and RAF/RAS/′ signaling activation, which is crucial in development, growth, and proliferation of lung
cancer. The aim of this study was to investigate the association of PHLPP expression with biological behavior and
prognosis of lung adenocarcinoma.
Methods: One hundred and fifty eight patients with pathologically documented stage I, II or IIIA lung adenocarcinoma
were recruited in this study. Expression of PHLPP, p-AKT and p-ERK were evaluated by immunohistochemistry (IHC) in
paraffin-embedded resected specimens. The correlation of their expression, which was dichotomized to low expression
(a score of 0, 1) versus high expression (a score of 2, 3), with the clinicopathological parameters and prognosis of the
patients also analyzed.
Results: High PHLPP expression rate in lung adenocarcinoma was 23.4 %. PHLPP expression level was significantly
associated with tumor differentiation (p = 0.025) and tumor stage (p = 0.024). Patients with high expression of PHLPP
showed significantly longer average survival time and higher 3 years survival rate than those with low expression of
PHLPP (45 months versus 38 months, 85.8 % versus 73.5 % respectively) (Log rank test x2 = 7.086, p =0.008).
A significant inverse correlation was observed between PHLPP expression and p-AKT (r = −0.523, p = 0.000) or
p-ERK (r = −0.530, p = 0.000).
Conclusion: Our results suggest that high levels of PHLPP might reflect a less aggressive lung adenocarcinoma
phenotype and predict better survival in patients with lung adenocarcinoma. PHLPP can be a potential prognostic
marker to screen patients for favorable prognoses.
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Background
PHLPP (PH domain leucine-rich repeats protein phos-
phatase) represents a family of novel Ser/Thr protein
phosphatases. PHLPP has been identified to negatively
regulate PI3K/Akt and RAF/RAS/ERK signaling activation
[1, 2]. PI3K/Akt pathway plays a central role in inhibiting
apoptosis in a variety of cell types including human cancer
cells [3]. The RAF/RAS/ERK pathway plays a critical role
in numerous cellular processes, including proliferation,
differentiation, survival, and motility. Hyperactivation of
RAF/RAS/ERK signaling is critical to the development of
many human malignancies tumor [2, 4]. The functional
importance of PHLPP as a tumor suppressor in different
types of cancer has been investigated in several recent
studies [1, 2, 5–13]. The expressions of PHLPPs were fre-
quently lost in a variety of human cancers, such as glioma
[6], colon cancer [7, 8], prostate cancer [9], gastric cancer
[10] and gallbladder cancer [11]. PHLPP expression was
significantly associated with progression-free survival in
gallbladder cancer [11]. The decrease in PHLPP1 level was
highly correlated with shorter survival for patients with
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pancreatic ductal adenocarcinoma [12]. Patients with low
PHLPP1 and PHLPP2 protein expressions have a poor
prognosis and PHLPP1 was an independent prognostic
factor in hypopharyngeal squamous cell carcinoma [13].
However, the expression and functional significance of
PHLPP in lung adenocarcinoma are not clear. The present
study aimed to investigate the association of PHLPP
expression with biological behavior, clinicopathological
characteristics and prognosis of lung adenocarcinoma.
Methods
Patients
Clinical data were compiled for 158 patients diagnosed
with lung adenocarcinoma in resected specimen from
2008 to 2010 in Taizhou Hospital of Zhejiang Province.
Variables included age, sex, date of diagnosis, stage at
diagnosis, and time of follow-up. The follow-up was per-
formed every 3 months after surgery for 2 years and
once every 6 months thereafter. The median follow-up
period was 38 months (range 3–56). Survival curves
based on stage at time of diagnosis showed the expected
patterns. All patients signed the informed consent. This
study was approved by the Ethics Committee of Taizhou
Hospital, and tissue specimen acquisition was carried
out in accordance with institutional guidelines.
Therapy
All patients had an Eastern Cooperative Oncology
Group (ECOG) perfor-mance status of 0 or 1, adequate
baseline organ function defined as a leucocyte count >
4 × 109 (absolute granulocyte count > 2 × 109, platelet
count > 100 × 109, normal liver function tests and serum
creatinine level < 1.4 mg/dl) and no other severe co-
morbid conditions. Patient stage was redetermined
according to the TNM Staging System of AJCC (7th
version, 2009). Surgery was performed as the initial
treatment for pathologically documented stage I, II and
IIIA. Postoperative first-line chemotherapy was added
depending on the TNM staging system. Cycles were
repeated every 3 weeks and four cycles were delivered in
II and IIIA patients.
Immunohistochemistry
At the tissue bank of Taizhou Hospital, tissue arrays
were prepared using a Beecher manual arrayer. Five-
micrometre-thick sections of the paraffin-embedded
tissue blocks were cut and mounted on polylysine
coated slides. They were dewaxed in xylene and rehy-
drated through a graded series of ethanol. After de-
paraffinization, antigen retrieval treatment was performed
at 120°c for 5 min in a 10 mM sodium citrate buffer
(pH 6.0). Endogenous peroxidase activity was blocked by
using a 3 % hydrogen peroxide solution at room
temperature for 15 min. Then, PHLPP (1:100, ab84978,
Abcam, Cambridge, England.), p-AKT (1:100, BS4007,
Bioworld Technology, MN,USA.) and p-ERK (BS5016,
1:200, Bioworld Technology, MN,USA.) were applied and
incubated overnight at 4°c. After that, a thorough washing
in a 0.01 M phosphate-buffered saline (PBS) solution was
done. The samples were then incubated with biotin-
labeled goat anti-rabbit secondary antibody. Subsequently,
binding sites of the primary antibody were visualized using
a Dako EnVison kit (Dako, Glostrup, Denmark) according
to the manufacturer’s instructions. Finally, sections were
counterstained with haematoxylin and mounted with
glycerol gelatin. The immunohistochemical specificity of
the antibodies was confirmed using two types of negative
controls: (i) substituting rabbit non-immune IgG for the
primary antibodies, and (ii) omitting the primary anti-
bodies from the staining protocol. Normal colonic mucosa
slide was used as a positive control.
Staining evaluation
Staining in tissues was evaluated by three pathologists
who were blinded to any clinical details related to the
patients. Membrane staining for PHLPP, cytoplasmic
staining for p-AKT and nucleus staining for p-ERK were
evaluated. The results of staining were scored according
to the intensity of staining with Fourtier system (level
0–3: negative = 0, weakest = 1, moderate = 2, strong = 3)
[14]. Then, these scores were divided into PHLPP low
expression group (0–1 point) and PHLPP high expression
group (2–3 point).
Statistical analysis
All statistical analyses were conducted using SPSS for
Windows (version 17.0). Count data statistics using chi-
square test. Associations between continuous variables
were analyzed by Pearson’s correlation test. Kaplan-Meier
survival curves were calculated for the patient subgroups
of interest and compared statistically, censoring for age
and stage, using the log-rank test. A p-value < 0.05 was
considered statistically significant.
Results
A total of 158 patients with histologically proven lung
adenocarcinoma were evaluated in this study. The ex-
pression of PHLPP, p-AKT and p-ERK in lung adenocar-
cinoma were evaluated by immunohistochemistry. The
relationship between the expression of PHLPP and the
clinicopathological characteristics of lung adenocarcin-
oma were analyzed. The results showed that the PHLPP
expression was associated with histological differenti-
ation and pathological T stage in lung adenocarcinoma
(Table 1). Figure 1 showed the proportion of patients
with different levels of PHLPP expression in lung adeno-
carcinoma. The structure of cases by the immunostain-
ing scores of PHLPP expression highlights the relatively
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low percentage (23.4 %) of cases with PHLPP, with score
2 (13.9 %) and 3 (9.5 %). Almost half (48.7 %) from all
cases were shown to have no expression of PHLPP.
Patients whose tumors stained at level 2 or greater were
designated high expression. Patients whose tumors
stained at level 1 or 0 were designated low expression.
Representative images of immunostaining of PHLPP,
p-Akt and p-ERK expression in lung adenocarcinoma
are shown in Fig. 2. There were 77.22 % (122/158) of
tumor tissues that had lost PHLPP expression. Among
those with loss of PHLPP expression tumor tissues, the
p-ERK positive rate was 63.11 % (77/122), p-AKT posi-
tive rate was 62.30 % (76/122), p-ERK and p-AKT both
positive rate was 25.41 % (31/122) (Table 2). A signifi-
cant negative correlation was observed between PHLPP
expression and p-AKT (r = −0.523, P = 0.000) or p-ERK
(r = −0.530, P = 0.000) (Table 2).
Among the 158 cases, there were 36 cases in which
lung adenocarcinoma tissue demonstrated high expres-
sion with PHLPP antibody and 122 cases with low ex-
pression of PHLPP. Patients with high expression of
PHLPP showed significantly longer average survival
time and higher 3 years survival rate than those with
low expression of PHLPP (38 months versus
45 months, 73.5 % versus 85.8 % respectively) (Log
rank test X2 = 7.086, P =0.008) (Fig. 3).
There were no significant differences in OS among the
PHLPP-negative & p-AKT- positive, PHLPP-negative &
p-ERK-positive and PHLPP-negative& p-AKT/p-ERK-
positive (p = 0.306, Fig. 4).
Discussion
Lung cancer is the most common malignant disease in
the world, and is the leading cause of cancer morbidity
and mortality in China, including both cities and country-
side [15]. Strong evidence is emerging in the basic science
literature that Akt and ERK are two signal transduction
proteins that play important roles in carcinogenesis and
chemoresistance [16]. PHLPP represents a family of novel
Ser/Thr protein phosphatases that have been identified to
negatively regulate signaling pathways activated including
PI3K/Akt [1] and RAF/RAS/ERK in cancer cells [2]. Con-
trolling the balance of protein phosphorylation is one of
the most important defense mechanisms provided by pro-
tein phosphatases to prevent aberrant hyperactivation of
signaling in cells [17]. Our studies here focused on eluci-
dating the tumor suppressor function of protein phospha-
tases, PHLPP, in lung adenocarcinoma. In this study, we
found that the expression of PHLPP were decreased in
76.5 % of lung adenocarcinoma tissues, which is consistent
Table 1 Distribution of PHLPP expression in lung adenocarcinoma





0 1 2 3
Age (Median = 59 years)
≤ 59 years 80 43 20 11 6 0.515
> 59 years 78 34 24 11 9
Gender
Male 42 21 9 8 4 0.357
Female 116 56 35 14 11
Differentiation
Well 24 2 12 7 3 0.025
Moderately 93 46 25 12 10
poorly 41 29 7 3 2
T stage
T1 25 12 3 6 4 0.024
T2 97 43 38 14 2
T3 36 22 3 2 9
N stage
N0 69 21 29 12 7 0.322
N1 40 26 8 4 2
N2 49 30 7 6 6
Stage
I 51 9 29 10 3 0.896
II 51 31 9 6 5
III 56 37 6 6 7
*p is PHLPP difference between high and low expression. High expression is 2
and 3, and lower expression is 0 and 1
Fig. 1 The proportion of patients with different levels of PHLPP
expression in lung adenocarcinoma. The structure of cases by the
immunostaining scores of PHLPP expression highlights the relatively
low percentage (23.4 %) of cases with PHLPP, with score 2 (13.9 %)
and 3 (9.5 %). Almost half (48.7 %) from all cases were shown to
have no expression of PHLPP
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with previously findings in colon cancer, prostate cancer,
chronic lymphocytic leukemia. Additionally, we found
PHLPP expression was significantly correlated with tumor
differentiation and T stage in lung adenocarcinoma. The
level of PHLPP1 expression was significant related to the
tumor T stage, in hypopharyngeal squamous cell carcin-
oma as reported by Zhou et al.
AKT and ERK signaling pathways are two important
signaling pathways in the lung cancer [18]. The two
signaling pathways are also the downstream signaling
molecules of epidermal growth factor receptor (EGFR)
signaling, which is mainly related with tumor occurrence
and development. They also play an important role in
the tolerance of chemoradiotherapy in lung cancer
[19]. A few studies which assessed the role of Akt
phosphorylation in NSCLC demonstrated that there
was a statistically significant difference in survival
between p-Akt-positive and p-Akt-negative patients
and this difference was independent of tumor stage
[20]. Activation of the ERK1/2 pathway is involved in
malignant transformation both in vitro and in vivo.
And the detection of immunoreactivity for p-ERK in
patients with NSCLC is associated with advanced and
aggressive tumors [21]. These data also suggest that
the analysis of ERK1/2 activation may be useful to
identify a subgroup of patients with a poorer progno-
sis. In the current study, we found PHLPP was in-
verse correlated with the expression of p-Akt and/or
p- ERK in human lung adenocarcinoma tissues. Our
findings here are consistent with our previous reports
that PHLPP negatively regulated signaling pathways
activated including PI3K/Akt and RAF/RAS/ERK in
different cancer cells [1, 2]. Moreover, in this study,
for the first time we detected PHLPP expressions in
human lung adenocarcinoma. Furthermore, we found
that low expression of PHLPP in lung adenocarcin-
oma highly correlated with shorter survival, which is
consistent with the recent report that [22] downregu-
lation of PHLPP expression contributed to hypoxia-
induced resistance to chemotherapy in colon cancer
cells. This may be related with the differences of
treatment outcomes. Wang et al. reported that the
OS time and relapse-free survival (RFS) time in
PHLPP1-positive patients were significantly longer
than in PHLPP1 negative patients and PHLPP1 was
Fig. 2 Representative images of immunostaining of PHLPP, p-Akt and p-ERK expression in lung adenocarcinoma. The tissue sections from the
lung adenocarcinoma were stained with the PHLPP (upper panels), p-AKT (middle panels) or p-ERK (lower panels) antibodies. The entire section
was assessed at low (100x) (left panels) and high (400x) power (right panels) magnification
Table 2 The correlation between PHLPP, p-AKT, p-ERK for lung
adenocarcinoma
Pearson coefficient(γ) p value
p-AKT PHLPP −0.52 0.000
p-ERK PHLPP −0.53 0.000
p-AKT p-ERK −0.15 0.055
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an independent prognostic factor for OS and RFS of
gastric cancer patient. Therefore, PHLPP may play an
important role in the dual function of two signal
pathways and would be better to inhibit the growth
of tumor.
Conclusions
In conclusion, our study suggests that high levels of
PHLPP might reflect a less aggressive lung adenocarcin-
oma phenotype and predict better survival in patients
with lung adenocarcinoma. PHLPP can be a potential
Fig. 3 Kaplan-Meier survival curves of patients with high and low expression of PHLPP. Patients with high expression of PHLPP showed
significantly longer average survival time and higher 3 years survival rate than those with low expression of PHLPP (Log rank test
x2 = 7.086, P =0.008)
Fig. 4 Comparison of Kaplan-Meier survival curves for patients with different p-AKT and p-ERK expression levels in patients with PHLPP low expression.
They are no differences in survival regardless of the expression of p-AKT and p-ERK in patients with low expression of PHLPP (P = 0.306)
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prognostic marker to screen patients for favorable
prognoses.
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